Clinical & Diagnostic Microbiology

Antimicrobial resistance (AMR) poses a growing global threat to public health, contributing to increasing morbidity and mortality rates. In 2019, AMR-related infections became the leading cause of death worldwide, surpassing even HIV/AIDS and Malaria¹. One of the major drivers of AMR is the inappropriate and often excessive use of antimicrobial agents. This is largely due to the challenge of accurately identifying the cause of infectious diseases based on clinical symptoms alone, which leads to the frequent empirical use of antibiotics “just in case.”

 IMMH addresses this issue by developing and promoting innovative diagnostic strategies and by evaluating the in-vitro and in-vivo efficacy of novel therapeutic candidates against multidrug-resistant (MDR) bacteria.

¹Antimicrobial Resistance Collaborators. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629-655. doi: 10.1016/S0140-6736(21)02724-0.